TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00485069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROP
Description: Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROP+L-Dopa
Description: Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
Study: NCT04454008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: executive function family training
Description: Intervention programs include executive function training for children with ADHD and parenting guidance for parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treat as usual
Description: Outpatient routine health education, behavioral guidance and family support
Study: NCT01116947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus
Description: Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus
Description: Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
Study: NCT03734393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIVD+/R+
Description: Liver from an HIV-infected deceased donor
Study: NCT03043742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived Autologous CD133+ Selected Cell Product
Description: Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
Study: NCT03477292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duration of antibiotic
Description: Duration of antibiotic for treatment of VAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duration of antibiotic
Description: Duration of antibiotic for treatment of VAP
Study: NCT03984396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials - Patient & Clinician
Description: deprescribing information for patient \& clinician
Study: NCT04101383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RinGlar®
Description: Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
Study: NCT04297631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vancomyscin
Description: Everyone gets the vancomyscin powder.
Study: NCT04074668

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT04101383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
Study: NCT03851770

Intervention type: OTHER
Group type: OTHER
Intervention: Characterization of Vagus nerve stimulation
Description: Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
Study: NCT03395626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ID-JPL934
Description: probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn starch
Study: NCT03337815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX and TwHF placebo
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TwHF and MTX placebo
Description: Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Study: NCT00811694

Intervention type: OTHER
Intervention: ocular blood flow measurements
Description: non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry

Intervention type: OTHER
Intervention: ocular blood flow measurements
Description: non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
Study: NCT03909048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive - Psychoeducation
Description: Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-interactive Psychoeducation
Description: Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
Study: NCT00607776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
Description: Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Drops
Study: NCT03328234

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Involved Field Irradiation (IFI)
Description: CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Involved Field Irradiation (IFI)
Description: CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
Study: NCT04534517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational Multifocal Contact Lens
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS® with HYDRACLEAR® PLUS
Description: The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
Study: NCT02597777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetyl Hexapeptide-8
Description: Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle
Description: Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
Study: NCT03100409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day.
Study: NCT01128296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
Study: NCT02527629

Intervention type: OTHER
Intervention: Decellularized human heart valves
Description: Decellularized human aortic heart valves
Study: NCT03732027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Transversus Abdominis Plane Block
Description: At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Rectus Sheath Block
Description: At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
Study: NCT02379013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volunteer with MRI
Description: functional MRI
Study: NCT03308422

Intervention type: BEHAVIORAL
Intervention: parental representations
Description: parental representations of the impact of the use of screens on their preschool children health and development
Study: NCT04232930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
Study: NCT03934216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on Specified Days
Study: NCT01824888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JUC solution
Description: 1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propan-2-ol
Description: 1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
Study: NCT01573000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
Description: Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
Description: Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
Study: NCT00163566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Study: NCT04363060

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Azithromycin with amoxicillin/clavulanate
Description: Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate
Description: Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
Study: NCT02484144

Intervention type: OTHER
Intervention: modern information
Description: information by video for coronarography

Intervention type: OTHER
Intervention: usual information
Description: usual information for coronarography

Intervention type: OTHER
Intervention: usual information
Description: usual information for coronarography
Study: NCT03983538

Intervention type: OTHER
Intervention: Mathematical modeling to predict response to chemotherapy
Description: Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
Study: NCT02955953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC
Study: NCT01100853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Description: Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Description: Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
Study: NCT03205293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren
Study: NCT02697643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHCDS-based recommendations

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-tailored recommendations
Study: NCT03610893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone as perineural local anesthetic adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine as perineural local anesthetic adjuvant
Study: NCT00169676

Intervention type: OTHER
Intervention: observation
Description: registry and database for surgery outcomes
Study: NCT00629031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: 11 mg/kg for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections
Study: NCT06550843

Intervention type: PROCEDURE
Intervention: mesentery-guided division
Description: In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
Study: NCT03871036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: See experimental arm description for more details.
Study: NCT03570216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Description: Participants will perform a 30-minute session of moderate-intensity continuous exercise.
Study: NCT04074668

Intervention type: DRUG
Intervention: Iohexol Inj 300 milligrams/milliliter (mg/ml)
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: DRUG
Intervention: Iohexol Inj 300 milligrams/milliliter (mg/ml)
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: RADIATION
Intervention: PET/CT Scan
Description: Imaging used to visualize the kidneys and quantify renal metabolic activity

Intervention type: RADIATION
Intervention: PET/CT Scan
Description: Imaging used to visualize the kidneys and quantify renal metabolic activity

Intervention type: PROCEDURE
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.

Intervention type: PROCEDURE
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.